Skip to main content
Erschienen in: Journal of Cancer Survivorship 5/2016

17.02.2016 | Review

Ovarian cancer survivors’ quality of life: a systematic review

verfasst von: D. Ahmed-Lecheheb, F. Joly

Erschienen in: Journal of Cancer Survivorship | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The assessment of quality of life (QOL) among ovarian cancer (OC) patients has mainly focused on the acute phase of treatment. This systematic review examines studies measuring QOL in patients who survived OC after treatment and synthesizes results in order to assess QOL and patient-reported outcome (PRO) data at long-term follow-up.

Methods

Articles published in English between 1990 to November 2014 were identified with the databases MEDLINE and PubMed, using the specific keywords “OC survivors” combined with the terms, “QOL,” “health-related QOL,” and “PROs.” Data were reviewed for design, time since end of treatment, measurement tools, and outcomes (categorized in three topics: global QOL compared to controls, treatment sequelae, and intervention strategies).

Results

The initial search strategy provided 148 articles of which 31 were considered eligible. Most studies focused on epithelial OC, and only a few studies investigated survivors of ovarian germ cell tumor. More than 60 instruments of QOL measures were used in the corpus. Despite the persistence of psychological and physical symptoms, treatment sequelae, sexual problems, and fear of recurrence in some survivors, most studies demonstrated that OC survivors generally have good QOL compared to healthy women. Studies proposing interventions are lacking.

Conclusions and Implications for Cancer Survivor

OC survivors experience a wide range of sequelae that may persist for a long time and negatively impact QOL. Further large-scale research is needed to fully understand problems that have significant effects on QOL, in order to develop interventions and treatments suitable for women at need.
Literatur
1.
Zurück zum Zitat Les cancers en France en 2013. Collection État des lieux et des connaissances, ouvrage collectif édité par l’INCa, Boulogne-Billancourt, janvier 2014. Les cancers en France en 2013. Collection État des lieux et des connaissances, ouvrage collectif édité par l’INCa, Boulogne-Billancourt, janvier 2014.
2.
3.
Zurück zum Zitat Hess LM, Stehman FB. State of the science in ovarian cancer quality of life research: a systematic review. Int J Gynecol Cancer. 2012;22(7):1273–80.PubMedCrossRef Hess LM, Stehman FB. State of the science in ovarian cancer quality of life research: a systematic review. Int J Gynecol Cancer. 2012;22(7):1273–80.PubMedCrossRef
4.
Zurück zum Zitat Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95, S247YS257.CrossRef Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95, S247YS257.CrossRef
5.
6.
Zurück zum Zitat Lockwood-Rayermann S. Survivorship issues in ovarian cancer: a review. Oncol Nurs Forum. 2006;33(3):553–62.PubMedCrossRef Lockwood-Rayermann S. Survivorship issues in ovarian cancer: a review. Oncol Nurs Forum. 2006;33(3):553–62.PubMedCrossRef
7.
Zurück zum Zitat Roland KB, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. Psychooncology. 2013;22(11):2408–18.PubMedCrossRef Roland KB, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. Psychooncology. 2013;22(11):2408–18.PubMedCrossRef
8.
Zurück zum Zitat Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107:1075–85.PubMedCrossRef Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107:1075–85.PubMedCrossRef
9.
Zurück zum Zitat Williams S, Blessing JA, Liao S, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12:701–6.PubMed Williams S, Blessing JA, Liao S, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12:701–6.PubMed
10.
Zurück zum Zitat Swenson MM, MacLeod JS, Williams SD, Miller AM, Champion VL. Quality of life after among ovarian germ cell cancer survivors: a narrative analysis. Oncol Nurs Forum. 2003;30(3):380.PubMedCrossRef Swenson MM, MacLeod JS, Williams SD, Miller AM, Champion VL. Quality of life after among ovarian germ cell cancer survivors: a narrative analysis. Oncol Nurs Forum. 2003;30(3):380.PubMedCrossRef
11.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.PubMedCrossRef Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.PubMedCrossRef
12.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(6), e1000097.PubMedPubMedCentralCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(6), e1000097.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Matei D, Miller AM, Monahan P, Gershenson D, Zhao Q, Cella D, et al. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(25):4142–9.PubMedPubMedCentralCrossRef Matei D, Miller AM, Monahan P, Gershenson D, Zhao Q, Cella D, et al. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(25):4142–9.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Monahan PO, Champion VL, Zhao Q, Miller AM, Gershenson D, Williams SD, et al. Case-control comparison of quality of life in long-term ovarian germ cell tumor survivors: a gynecologic oncology group study. J Psychosoc Oncol. 2008;26(3):19–42.PubMedCrossRef Monahan PO, Champion VL, Zhao Q, Miller AM, Gershenson D, Williams SD, et al. Case-control comparison of quality of life in long-term ovarian germ cell tumor survivors: a gynecologic oncology group study. J Psychosoc Oncol. 2008;26(3):19–42.PubMedCrossRef
15.
Zurück zum Zitat Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25(19):2792–7.PubMedCrossRef Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25(19):2792–7.PubMedCrossRef
16.
Zurück zum Zitat Champion V, Williams SD, Miller A, Reuille KM, Wagler-Ziner K, Monahan PO, et al. Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;105(3):687–94.PubMedPubMedCentralCrossRef Champion V, Williams SD, Miller A, Reuille KM, Wagler-Ziner K, Monahan PO, et al. Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;105(3):687–94.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135(3):510–7.PubMedCrossRef Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135(3):510–7.PubMedCrossRef
18.
Zurück zum Zitat Teng FF, Kalloger SE, Brotto L, McAlpine JN. Determinants of quality of life in ovarian cancer survivors: a pilot study. J Obstet Gynaecol Can. 2014;36(8):708–15.PubMedCrossRef Teng FF, Kalloger SE, Brotto L, McAlpine JN. Determinants of quality of life in ovarian cancer survivors: a pilot study. J Obstet Gynaecol Can. 2014;36(8):708–15.PubMedCrossRef
19.
Zurück zum Zitat Stavraka C, Ford A, Ghaem-Maghami S, Crook T, Agarwal R, Gabra H, et al. A study of symptoms described by ovarian cancer survivors. Gynecol Oncol. 2012;125(1):59–64.PubMedCrossRef Stavraka C, Ford A, Ghaem-Maghami S, Crook T, Agarwal R, Gabra H, et al. A study of symptoms described by ovarian cancer survivors. Gynecol Oncol. 2012;125(1):59–64.PubMedCrossRef
20.
Zurück zum Zitat Paxton RJ, Garcia-Prieto C, Berglund M, Hernandez M, Hajek RA, Handy B, et al. A randomized parallel-group dietary study for stages II-IV ovarian cancer survivors. Gynecol Oncol. 2012;124(3):410–6.PubMedCrossRef Paxton RJ, Garcia-Prieto C, Berglund M, Hernandez M, Hajek RA, Handy B, et al. A randomized parallel-group dietary study for stages II-IV ovarian cancer survivors. Gynecol Oncol. 2012;124(3):410–6.PubMedCrossRef
21.
Zurück zum Zitat Greimel E, Daghofer F, Petru E. Prospective assessment of quality of life in long-term ovarian cancer survivors. Int J Cancer. 2011;128(12):3005–11.PubMedCrossRef Greimel E, Daghofer F, Petru E. Prospective assessment of quality of life in long-term ovarian cancer survivors. Int J Cancer. 2011;128(12):3005–11.PubMedCrossRef
22.
Zurück zum Zitat Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009;114(2):353–9.PubMedCrossRef Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009;114(2):353–9.PubMedCrossRef
23.
Zurück zum Zitat Stevinson C, Tonkin K, Capstick V, Schepansky A, Ladha AB, Valance JK, et al. A population-based study of the determinants of physical activity in ovarian cancer survivors. J Phys Act Health. 2009;6(3):339–46.PubMedCrossRef Stevinson C, Tonkin K, Capstick V, Schepansky A, Ladha AB, Valance JK, et al. A population-based study of the determinants of physical activity in ovarian cancer survivors. J Phys Act Health. 2009;6(3):339–46.PubMedCrossRef
24.
Zurück zum Zitat Stevinson C, Capstick V, Schepansky A, Tonkin K, Vallance JK, Ladha AB, et al. Physical activity preferences of ovarian cancer survivors. Psycho-Oncology. 2009;18(4):422–8.PubMedCrossRef Stevinson C, Capstick V, Schepansky A, Tonkin K, Vallance JK, Ladha AB, et al. Physical activity preferences of ovarian cancer survivors. Psycho-Oncology. 2009;18(4):422–8.PubMedCrossRef
25.
Zurück zum Zitat Stevinson C, Steed H, Faught W, Tonkin K, Vallance JK, Ladha AB, et al. Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning. Int J Gynecol Cancer. 2009;19(1):73–8.PubMedCrossRef Stevinson C, Steed H, Faught W, Tonkin K, Vallance JK, Ladha AB, et al. Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning. Int J Gynecol Cancer. 2009;19(1):73–8.PubMedCrossRef
26.
Zurück zum Zitat Stevinson C, Faught W, Steed H, Tonkin K, Ladha AB, Vallance JK, et al. Associations between physical activity and quality of life in ovarian cancer survivors. Gynecol Oncol. 2007;106(1):244–50.PubMedCrossRef Stevinson C, Faught W, Steed H, Tonkin K, Ladha AB, Vallance JK, et al. Associations between physical activity and quality of life in ovarian cancer survivors. Gynecol Oncol. 2007;106(1):244–50.PubMedCrossRef
27.
Zurück zum Zitat Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA. Morbidity associated with “self-rated health” in epithelial ovarian cancer survivors. BMC Cancer. 2009;9:2.PubMedPubMedCentralCrossRef Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA. Morbidity associated with “self-rated health” in epithelial ovarian cancer survivors. BMC Cancer. 2009;9:2.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol. 2008;108(2):348–54.PubMedCrossRef Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol. 2008;108(2):348–54.PubMedCrossRef
29.
Zurück zum Zitat Liavaag AH, Dorum A, Fossa SD, Tropé C, Dahl AA. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol. 2007;25:2049–56.PubMedCrossRef Liavaag AH, Dorum A, Fossa SD, Tropé C, Dahl AA. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol. 2007;25:2049–56.PubMedCrossRef
30.
Zurück zum Zitat Fox SW, Lyon D. Symptom clusters and quality of life in survivors of ovarian cancer. Cancer Nurs. 2007;30(5):354–61.PubMedCrossRef Fox SW, Lyon D. Symptom clusters and quality of life in survivors of ovarian cancer. Cancer Nurs. 2007;30(5):354–61.PubMedCrossRef
31.
Zurück zum Zitat Ferrell B, Cullinane CA, Ervine K, Melancon C, Uman GC, Juarez G. Perspectives on the impact of ovarian cancer: women’s views of quality of life. Oncol Nurs Forum. 2005;32(6):1143–9.PubMedCrossRef Ferrell B, Cullinane CA, Ervine K, Melancon C, Uman GC, Juarez G. Perspectives on the impact of ovarian cancer: women’s views of quality of life. Oncol Nurs Forum. 2005;32(6):1143–9.PubMedCrossRef
32.
Zurück zum Zitat Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. “What doesn’t kill you makes you stronger”: an ovarian cancer survivor survey. Gynecol Oncol. 2001;83(3):537–42.PubMedCrossRef Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. “What doesn’t kill you makes you stronger”: an ovarian cancer survivor survey. Gynecol Oncol. 2001;83(3):537–42.PubMedCrossRef
33.
Zurück zum Zitat Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, et al. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008;18(6):1183–93.PubMedCrossRef Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, et al. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008;18(6):1183–93.PubMedCrossRef
34.
Zurück zum Zitat Wenzel LB, Donnelly JP, Foweler JM, Habbal R, Taylor TH, Aziz N, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psycho-Oncology. 2002;11:142–53.PubMedCrossRef Wenzel LB, Donnelly JP, Foweler JM, Habbal R, Taylor TH, Aziz N, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psycho-Oncology. 2002;11:142–53.PubMedCrossRef
35.
Zurück zum Zitat Gross AH, Cromwell J, Fonteyn M, Matulonis UA, Hayman LL. Hopelessness and complementary therapy use in patients with ovarian cancer. Cancer Nurs. 2013;36(4):256–64.PubMedCrossRef Gross AH, Cromwell J, Fonteyn M, Matulonis UA, Hayman LL. Hopelessness and complementary therapy use in patients with ovarian cancer. Cancer Nurs. 2013;36(4):256–64.PubMedCrossRef
36.
Zurück zum Zitat Andersen MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA. Involvement in decision-making about treatment and ovarian cancer survivor quality of life. Gynecol Oncol. 2012;124(3):465–70.PubMedCrossRef Andersen MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA. Involvement in decision-making about treatment and ovarian cancer survivor quality of life. Gynecol Oncol. 2012;124(3):465–70.PubMedCrossRef
37.
Zurück zum Zitat Kornblith AB, Mirabeau-Beale K, Lee H, Goodman AK, Penson RT, Pereira L, et al. Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol. 2010;28(5):451–69.PubMedCrossRef Kornblith AB, Mirabeau-Beale K, Lee H, Goodman AK, Penson RT, Pereira L, et al. Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol. 2010;28(5):451–69.PubMedCrossRef
38.
Zurück zum Zitat Otis-Green S, Ferrell B, Sun V, Spolum M, Morgan R, Macdonald D. Feasibility of an ovarian cancer quality-of-life psychoeducational intervention. J Cancer Educ. 2008;23(4):214–21.PubMedCrossRef Otis-Green S, Ferrell B, Sun V, Spolum M, Morgan R, Macdonald D. Feasibility of an ovarian cancer quality-of-life psychoeducational intervention. J Cancer Educ. 2008;23(4):214–21.PubMedCrossRef
39.
Zurück zum Zitat Holzner B, Kemmler G, Meraner V, Maislinger A, Kopp M, Bodner T, et al. Fatigue in ovarian carcinoma patients: a neglected issue? Cancer. 2003;97(6):1564–72.PubMedCrossRef Holzner B, Kemmler G, Meraner V, Maislinger A, Kopp M, Bodner T, et al. Fatigue in ovarian carcinoma patients: a neglected issue? Cancer. 2003;97(6):1564–72.PubMedCrossRef
40.
Zurück zum Zitat Ferrel B, Smith SL, Cullinane CA, Melancon C. Psychological well-being and quality of life in ovarian cancer survivors. Cancer. 2003;98:1061–71.CrossRef Ferrel B, Smith SL, Cullinane CA, Melancon C. Psychological well-being and quality of life in ovarian cancer survivors. Cancer. 2003;98:1061–71.CrossRef
41.
Zurück zum Zitat Ferrell BR, Smith SL, Juarez G, Melancon C. Meaning of illness and spirituality in ovarian cancer survivors. Oncol Nurs Forum. 2003;30(2):249–57.PubMedCrossRef Ferrell BR, Smith SL, Juarez G, Melancon C. Meaning of illness and spirituality in ovarian cancer survivors. Oncol Nurs Forum. 2003;30(2):249–57.PubMedCrossRef
42.
Zurück zum Zitat Ersek M, Ferrell BR, Dow KH, Melancon CH. Quality of life in women with ovarian cancer. West J Nurs Res. 1997;19(3):334–50.PubMedCrossRef Ersek M, Ferrell BR, Dow KH, Melancon CH. Quality of life in women with ovarian cancer. West J Nurs Res. 1997;19(3):334–50.PubMedCrossRef
44.
Zurück zum Zitat Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy—ovarian. J Clin Oncol. 2001;19:1809–17.PubMed Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy—ovarian. J Clin Oncol. 2001;19:1809–17.PubMed
45.
Zurück zum Zitat Ferrell B, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4(6):523–31.PubMedCrossRef Ferrell B, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4(6):523–31.PubMedCrossRef
46.
Zurück zum Zitat Waterhouse J, Metcalfe MC. Development of the sexual adjustment questionnaire. Oncol Nurs Forum. 1986;13:53–9.PubMed Waterhouse J, Metcalfe MC. Development of the sexual adjustment questionnaire. Oncol Nurs Forum. 1986;13:53–9.PubMed
47.
Zurück zum Zitat Zeltzer LK, Lu Q, Leisenring W, et al. Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2008;17(2):435–46.PubMedCrossRef Zeltzer LK, Lu Q, Leisenring W, et al. Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2008;17(2):435–46.PubMedCrossRef
48.
Zurück zum Zitat Ashing-Giwa KT, Tejero JS, Kim J, Padilla GV, Hellemann G. Examining predictive models of HRQOL in a population-based, multiethnic sample of women with breast carcinoma. Qual Life Res. 2007;16(3):413–28.PubMedCrossRef Ashing-Giwa KT, Tejero JS, Kim J, Padilla GV, Hellemann G. Examining predictive models of HRQOL in a population-based, multiethnic sample of women with breast carcinoma. Qual Life Res. 2007;16(3):413–28.PubMedCrossRef
49.
Zurück zum Zitat Sweeney C, Schmitz KH, Lazovich D, Virnig BA, Wallace RB, Folsom AR. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst. 2006;98(8):521–9.PubMedCrossRef Sweeney C, Schmitz KH, Lazovich D, Virnig BA, Wallace RB, Folsom AR. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst. 2006;98(8):521–9.PubMedCrossRef
50.
Zurück zum Zitat Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol. 2004;22:881–9.PubMedCrossRef Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol. 2004;22:881–9.PubMedCrossRef
51.
Zurück zum Zitat Brotto LA, Heiman JR. Mindfulness in sex therapy: applications for women with sexual difficulties following gynecologic cancer. Sex Relationship Ther. 2007;22:1468–994. Brotto LA, Heiman JR. Mindfulness in sex therapy: applications for women with sexual difficulties following gynecologic cancer. Sex Relationship Ther. 2007;22:1468–994.
53.
Zurück zum Zitat Weis J. Support groups for cancer patients. Support Care Cancer. 2003;11:63–8.CrossRef Weis J. Support groups for cancer patients. Support Care Cancer. 2003;11:63–8.CrossRef
Metadaten
Titel
Ovarian cancer survivors’ quality of life: a systematic review
verfasst von
D. Ahmed-Lecheheb
F. Joly
Publikationsdatum
17.02.2016
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 5/2016
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-016-0525-8

Weitere Artikel der Ausgabe 5/2016

Journal of Cancer Survivorship 5/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.